• Actinium Pharmaceuticals Inc., of New York, said it intends to raise up to $20 million in new funds to be used for further clinical development of immunotherapeutic candidates Actimab-A and lomab-B in hematologic malignancies and for continued preclinical development of additional drug candidates in solid cancer indications, as well as for general corporate purposes.